KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Accounts Payables (2016 - 2026)

Palvella Therapeutics has reported Accounts Payables over the past 10 years, most recently at $4.2 million for Q4 2022.

  • Quarterly Accounts Payables fell 51.75% to $4.2 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $4.2 million through Dec 2022, down 51.75% year-over-year, with the annual reading at $4.2 million for FY2022, 51.75% down from the prior year.
  • Accounts Payables was $4.2 million for Q4 2022 at Palvella Therapeutics, up from $3.6 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $14.1 million in Q1 2022 and troughed at $1.8 million in Q4 2020.
  • The 5-year median for Accounts Payables is $4.3 million (2020), against an average of $5.5 million.
  • Year-over-year, Accounts Payables tumbled 82.03% in 2020 and then soared 381.76% in 2021.
  • A 5-year view of Accounts Payables shows it stood at $9.1 million in 2018, then grew by 9.11% to $9.9 million in 2019, then tumbled by 82.03% to $1.8 million in 2020, then soared by 381.76% to $8.6 million in 2021, then crashed by 51.75% to $4.2 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Accounts Payables are $4.2 million (Q4 2022), $3.6 million (Q3 2022), and $1.9 million (Q2 2022).